Evidence map›Paper›PMID 37376227›Full record

ArticlePharmaceutics2023

RETRACTED: Zhou et al. Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation.

Shiwei Zhou, Obinna N Obianom, Jiangsheng Huang, Dong Guo, Hong Yang, Qing Li, Yan Shu

RetractedOpen access · goldAbstract readRetraction Notice
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Shiwei ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0000-0001-5411-4378
Obinna N ObianomDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
Jiangsheng HuangDepartment of Thyroid Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
Dong GuoDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
Hong YangDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD 21201, USA.
Qing LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.ORCID 0000-0002-1787-4180
Yan ShuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China.
University of Maryland, Baltimore · USCentral South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The authors and the journal retract the article, 'Pyrvinium Treatment Confers Hepatic Metabolic Benefits via β-Catenin Downregulation and AMPK Activation' [...].

Identifiers

PMID37376227
PMCPMC10301172
OpenAlexW4378831114

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.